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Summary Binding of the cytostatic drug carboplatin to DNA was studied in solution, in RIF-I and CHO cell
lines and in human buccal cells after in vitro or in situ drug exposure. Results were compared with DNA
adduction by cisplatin. The rate of binding in solution, determined by atomic absorption spectroscopy, was 35
times lower for carboplatin than for cisplatin. Adduct formation in cells in vitro was determined in a
quantitative immunostaining assay. Staining intensities after carboplatin treatment were at least 29 times lower
than after an equimolar dose of cisplatin. For RIF-I and CHO cells, maximum levels of carboplatin-induced
DNA modification were obtained 24 h after treatment; these levels correlated with cell killing. Adduct-specific
staining in buccal cells from two carboplatin-treated patients increased 5-7 fold between 0 and 14 h after
infusion, reaching a maximum at 10- 14 h. This strongly contrasts with buccal cells from a cisplatin-treated
patient, in which the adduct-specific staining signal increased by only 23% between 0 and 6 h after infusion,
and then declined. This difference in the rate of adduct formation in vivo is consistent with the in vitro data.
The drug cis-diamminedichloroplatinum(II) (cisDDP or cis-
platin; Rosenberg, 1985) is widely used in the treatment of
solid malignancies. CisDDP is also an extremely toxic drug,
with nephrotoxicity and neuropathy being the dose-limiting
factors. To decrease these side effects, several platinum com-
pounds have been synthesised and studied during the last
decades. The second generation drug carboplatin (cis-
diammine( ,1-cyclobutanedicarboxylato)platinum(II)) was
found to be active against a wide spectrum of tumours, its
nephrotoxicity is absent or low (Calvert et al., 1984; Evans et
al., 1983), and its major toxic side effect is thrombocytopenia
(Calvert et al., 1982). The tissue distribution ofcarboplatin is
almost the same as that of cisDDP (Siddik et al., 1988).
Carboplatin differs from cisDDP in its pharmacokinetics, i.e.
the half-lives of free (ultrafilterable) platinum in blood
plasma from both laboratory animals and humans are longer
for carboplatin than for cisDDP (Litterst, 1984; Siddik et al.,
1987). The slow decrease of free carboplatin in plasma is in
agreement with its slow and partially reversible in vitro bind-
ing to plasma proteins (Litterst, 1984; Siddik et al., 1987).
Differences in pharmacokinetics might explain why carbo-
platin can be active in patients with cisDDP-resistant
tumours (Evans et al., 1983; Calvert et al., 1982). In the
'clinic, about four times higher chemotherapeutic doses of
carboplatin are needed than cisDDP. This is consistent with
the capacity to kill cells in vitro, which, for a given dose, is
lower for carboplatin than for cisDDP (Bedford et al., 1987;
Kuppen et al., 1988).
The interaction of carboplatin and cisDDP with DNA is
considered to be important for their antitumour activity
(Zwelling & Kohn, 1979; Lippard, 1982; Rosenberg, 1985;
Reedijk, 1987). Evidence has been presented that
carboplatin-DNA adducts, with the exception of mono-
adducts, are chemically similar to cisDDP-DNA adducts
(Knox et al., 1986; Dijt, 1989). Because of the presumed
importance of DNA adduct formation by platinum-
containing drugs, we have previously studied cisDDP-DNA
adducts in animal tissues, in cultured cells, and in cells from
cancer patients using a quantitative immunoperoxidase
method. The cisDDP-DNA adducts were assayed by an
antiserum raised against cisDDP-modified DNA, which also
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recognised carboplatin-DNA adducts in a competitive ELISA
and in a quantitative immunocytochemical peroxidase assay
(Terheggen et al., 1988, 1989).
Little is known on the formation of carboplatin-DNA
adducts in cells or patients. Such knowledge might eventually
contribute to the optimisation of patient anti-cancer treat-
ment. We have therefore studied the binding of carboplatin
to DNA in cultured cells and in buccal mucosa cells from
carboplatin-treated cancer patients. The results were com-
pared with adduct formation in DNA in solution and with
the cytotoxic effects of carboplatin in vitro.
Materials and methods
DNA adductformation in solution
One 1tmol calf thymus DNA-P in phosphate-buffer (0.2 mM
Na2HPO4, 0.8 mM NaH2PO4, 3 mM NaCI; pH 7.4), pretreated
with DNase S, (816 units mg-' DNA; Sigma, St. Louis,
MO), was incubated with 0.4tLmol carboplatin (Carboplatin,
Bristol-Myers, Weesp, The Netherlands) or 60 nmol cisDDP
(Platinol, Bristol-Myers) for 0-72 h at 37°C in a volume of
1 ml. After 3-72 h, DNA was precipitated with ethanol over-
night at - 20°C, washed twice with 70% aqueous ethanol to
remove free platinum from DNA, and hydrolysed
(Fichtinger-Schepman et al., 1987). The platinum content of
DNA samples was assessed with a Spectra Zeeman 30
flameless atomic absorption spectrometer (Varian, Zug,
Switzerland).
Cells and treatments
Murine RIF-1 cells (provided by Dr R.F. Kallman; Stanford
University, CA) and CHO cells were grown as monolayer
cultures in Ham's FIO medium (Flow Laboratories, Irvine,
UK) + 10% foetal calf serum (FCS; Sera-Lab, Sussex, UK)
under standard conditions (37°C in a humidified 5%
C02:95% air mixture). RIF-I cells were maintained involving
alternating growth cycles in vivo and in vitro (Twentyman et
al., 1980). CHO cells were passaged weekly ten times before
returning to a frozen stock. RIF-I and CHO cells were
seeded into 60 x 15 mm dishes and treated 2-4 days later
when cells were in logarithmic growth phase. Freshly
obtained buccal cells from volunteers (103-104 cells per per-
son) were washed twice in RPMI 1640 medium prior to
incubation with 75-30011M carboplatin for 1-6h or with
16.7lM cisDDP for 1 h.
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In a first series of experiments with RIF-1 and CHO, cells
were treated for 2 h with carboplatin (0-4.7 mM) or cisDDP
(5 JAM, RIF-1; 16.7JAM, CHO), washed twice, trypsinised, and
prepared for immunocytochemical analysis. In a second
series of experiments, RIF-1 cells were incubated for 1 h with
1.2 mM (RIF-1) or 300JAM (CHO) carboplatin, washed twice,
cultured in platinum-free medium for 0-48 h, and prepared
for immunocytochemical analysis. In a third series of
experiments, approximately 2 x 105 RIF-1 and CHO cells
were treated for 1 h with 0- 1.2 mM carboplatin or with
6.7 JAM (RIF-1) or 33.3 JAM (CHO) cisDDP, washed twice,
cultured for 24 h in platinum-free medium, trypsinised, and
assayed for their colony forming ability. Colony formation
was assayed by culturing for 7-10 days. The surviving frac-
tion was expressed as the plating efficiency relative to that of
untreated cells. An aliquot of the cells was used for the
immunocytochemical assay of platinum-DNA binding
(Terheggen et al., 1988). In a fourth series of experiments,
approximately 108 RIF-I cells were incubated for I h with
1.2 mM carboplatin, washed twice, cultured for 0, 6 or 24 h
in platinum-free medium, and harvested. Cytospin slides were
made from an aliquot (approximately 104 cells). DNA was
isolated from the remaining cells essentially as described
(Fichtinger-Schepman et al., 1987) and hydrolysed in I M
HCI for I h at 70°C. Platinum concentrations were assessed
by atomic absorption spectroscopy (AAS).
Human studies
The patients studied were treated at The Netherlands Cancer
Institute. Patient A was treated for testicular cancer, patients
B and C for ovarian cancer. Patients A and B were treated
with 2 h infusions of 600 and 800 mg m-2 carboplatin,
respectively. Patient C received a 4 h infusion of 75 mg m-2
cisDDP. These treatments were combined with either
etoposide (500 mg m-2, patient A) or cyclophosphamide
(750 mg m-2, patient C). The patients had been treated with
cisDDP- or carboplatin-based chemotherapy 2 months
(patient C), 3 months (patient A), or 10 months (patient B)
earlier. Buccal cells were collected from patients (after in-
formed consent) and healthy volunteers by wiping the inner
side of the cheek with a cotton swab. Buccal cells from
patients were collected immediately before infusion with
cisDDP or carboplatin, and at between 0 and 48 h after the
end of infusions. Cells were suspended in cold (0-4°C)
RPMI 1640 medium (Gibco, Paisley, UK).
Immunocytochemical assay
The preparation of antiserum NKI-A59 against cisDDP-
modified DNA has been described previously (Terheggen et
al., 1988; Poirier et al., 1982). NKI-A59 was used without
purification at a dilution of 1: 1800. The immunostaining
assay was carried as described (Terheggen et al., 1988). Slides
from the same experiment were stained simultaneously and
all samples were stained in two independent tests. The den-
sity of the adduct-specific nuclear staining was measured at
the single-cell level as previously reported (Terheggen et al.,
1988). The nuclear staining density, expressed in arbitrary
units, represents the integrated optical density per nucleus. In
each slide, the nuclear staining density of 15 randomly
selected nuclei was measured (two slides per point). To com-
pare adduct levels of cells which had been incubated with
different drug doses, and/or during different incubation
times, the nuclear staining density was expressed per JAM
platinum per hour. The ratios of nuclear staining density
JAM-i drug, used for the comparison of carboplatin vs
cisDDP within a certain cell type, were obtained from the
average values of all available ratios of nuclear staining
density JAM' drug.
Statistics
Levels of significance were calculated using analysis of
variance followed by Scheffe's test (Armitage, 1971). The best
fitting line between points and the correlation coefficient,
based on a 95% confidence interval, were calculated by linear
regression analysis.
Results
Binding ofcarboplatin and cisDDP to DNA in solution
Carboplatin and cisDDP were reacted with calf thymus
DNA for 0-72 h, free platinum was removed, and the
platinum-DNA binding was measured by AAS. On a molar
basis, 6.7 times more carboplatin than cisDDP was added to
DNA. Figure 1 shows that the cisDDP-DNA binding
reached a maximum between 6 and 24 h. In contrast, the
reaction of carboplatin with DNA was still progressing after
24 h. The extent of carboplatin-DNA binding increased
linearly with time (correlation coefficient >0.99, P <0.01).
The reaction rate of cisDDP with DNA, measured between 0
and 6 h, was 35 times higher than the reaction rate of
carboplatin with DNA, measured between 0-72 h. The max-
imum platinum-nucleotide ratios were 5.8 x 10-2 for cisDDP
(mean from 20, 24 and 48 h) and 1.7 x 10-2 for carboplatin
(at 72 h).
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Figure 1 Binding of carboplatin and cisDDP to DNA in solu-
tion, expressed as platinum-nucleotide ratio, vs the incubation
time (h). Carboplatin (0.4fmol) or cisDDP (60 nmol) were
incubated with 1 JAmol DNA-P at 37°C in a total volume of 1 ml.
At the indicated time points DNA was precipitated and analysed
for platinum content by AAS.
Platinum-DNA adducts in cultured cells directly after exposure
In these experiments, the initial carboplatin-DNA binding in
cultured cells was determined and compared with cisDDP-
DNA binding. RIF-1 and CHO cells were incubated for 2 h
with carboplatin in concentrations up to 120JAM (RIF-1) or
4.72 mM (CHO). Chosen drug doses for the respective
experiments were shown to give positive immuno-
cytochemical staining and/or measurable levels of cell death.
The nuclear staining density increased linearly with the dose
(Figure 2; correlation coefficient >0.99, P <0.01). The
difference in nuclear staining density JAM- platinum between
RIF-1 and CHO differed by up to a factor of40. In the same
experiment, RIF-1 and CHO cells were incubated for 2 h
with cisDDP at concentrations of 5JAM for RIF-1 and
16.7 JAM for CHO. The nuclear staining densities immediately
after exposure were 201 and 190 arbitrary units for RIF-1
and CHO cells, respectively. The nuclear staining density
AM-I cisDDP was therefore only 4.4 ± 0.1 fold higher for
RIF-I than for CHO cells, in contrast to the high value
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cell line, a 64 ± 13 (for RIF-1 cells) and 527 ± 35 (for CHO
cells) times higher molar concentration of carboplatin was
required to achieve the same level of nuclear staining density
as after cisDDP.
When buccal cells from healthy volunteers were incubated
with carboplatin, the nuclear staining densities were approxi-
mately linear both with dose (correlation coefficient >0.99,
P <0.01) and with incubation time (correlation coefficient
>0.97, P <0.05; Figure 3). The nuclear staining density in
these buccal cells (calculated from the data in Figure 3)
ranged between 0.2 and 0.7 arbitrary units LM-' platinum
h-'. The corresponding values for RIF-1 were almost the
same (0.2-0.5 arbitrary units jM-' platinum h-'; calculated
from Figure 4), but much lower figures were calculated for
CHO cells (0.01-0.1 arbitrary units JM-' platinum h-i; also
from Figure 4). Buccal cells were also treated for 1 h with
16.7I1M cisDDP (results not shown). This revealed that, in
agreement with the findings for RIF-1 and CHO cells, much
more carboplatin than cisDDP was required to obtain the
same nuclear staining density in buccal cells (i.e. by a factor
29 ± 5).
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Figure 2 Nuclear staining density (arbitrary units) vs the concen-
tration of carboplatin. RIF-I and CHO cells were treated for 2 h
with carboplatin and immunostained for platinum-DNA binding.
Each point represents the mean ± s.e. (bar) from two slides; 30
nuclei per point.
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Figure 4 Nuclear staining density vs time after exposure to
carboplatin. Plateau-phase RIF-1 and CHO cells were incubated
for 1 h with 300JAM (RIF-1) or 1.2 mM (CHO) carboplatin,
washed, and cultured in platinum-free medium. At the indicated
time points cells were immunostained for platinum-DNA binding.
Each point represents the mean ± s.e. from two slides; 30 nuclei
per point.
Carboplatin-DNA binding versus time after exposure
To study the kinetics of carboplatin-DNA adduct formation,
plateau-phase cells were incubated for I h with 300ylM (RIF-1)
or 1.2 mM (CHO) carboplatin, washed, and cultured again in
platinum-free medium for 0-48 h. These doses gave approxi-
mately equal adduct levels, as shown in pilot experiments. At
3 h, the nuclear staining density in CHO cells was still very
low, whereas no adducts could be detected in RIF-1 cells
(Figure 4). The nuclear staining density strongly increased
between 6 and 24 h after exposure. Adduct levels were about
the same in both cell lines after using a four times higher
concentration of carboplatin for CHO cells. In another
experiment (fourth series), RIF-1 cells were treated for 1 h
with 1.2 mm carboplatin and harvested at different times
thereafter. The nuclear staining densities at 0, 6 and 24 h
post-treatment were 47 ± 26, 156 ± 21 and 287 ± 26, respec-
tively, confirming the slow and progressive rise over this time
period. The platinum-DNA binding, as measured by AAS,
was undetectable at 0 h after exposure (i.e. platinum/
nucleotide ratio < 10-5), while the platinum/nucleotide ratios
were 1.7 x 10-5 at 6 h, and 2.5 x 10' at 24 h. This shows
that, at 24 h, for each (arbitrary) immunostaining unit about
8,500 platinum molecules per nucleus (1010 nucleotides) were
present. It also indicates that the detection limit of AAS was
higher (i.e. worse) than for immunocytochemistry. Since
these AAS data were just above the detection limit it could
not be definitely concluded that the nuclear staining densities
paralleled total levels of platinum-DNA binding.
Survival and DNA adducts
To investigate whether adduct levels parallel cell kill, the
sensitivity of RIF-I cells and CHO cells to carboplatin was
related to the extent of carboplatin-DNA binding. Figure 5
shows the results from the clonogenic assay after a 1 h
T 1 h incubation with carboplatin in which cells were seeded 24 h
1 h after exposure. RIF-1 cells were approximately four times
more sensitive to carboplatin than CHO cells. In this experi-
ment, RIF-I and CHO cells were also incubated for I h with
6.7(iM (RIF-1) or 33.3 .LM (CHO) cisDDP, giving rise to
surviving fractions of 1.8 x 10-' and 3.6 ± 10-', respectively.
300 400 From these data it was estimated that a 35 times higher
molar concentration of carboplatin than that of cisDDP was
In buccal cells vs the required to obtain the same toxic effects in these cell lines.
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addition, differences in cell survival between carboplatin and
cisDDP were paralleled by differences in DNA adduct levels
(Figure 7).
DNA adducts in cancerpatients
To test whether the time course ofadduct formation found in
DNA in solution and in cultured cells also applies to human
cells in situ, three patients were investigated from which
buccal cells were collected at different times after cisplatin or
carboplatin therapy. Highest nuclear staining densities were
measured 10 h (patient A) or 14 h (patient B) after the end of
the infusions with carboplatin (Figure 8). The nuclear stain-
ing densities directly after the infusions did not differ
significantly (P <0.05) from pretreatment, i.e. background,
values. The nuclear staining density increased about 9-
(patient A) or 5-fold (patient B) between the end of the
infusion and the time-point of highest adduct levels. The
nuclear staining density increased significantly (P <0.01)
Figure 5 Survival of RIF-l and CHO cells after treatment with
carboplatin. Cells were treated for 1 h with 0-1.2 mm carbo-
platin, washed, cultured for 24 h in a platinum-free medium, and
tested in a clonogenic assay. Each point represents the mean
surviving fraction + s.e. from two independent experiments.
180
RIF-1
150-
o~~~~~~~~~~~
c 120
90
T CHO
0)
~60
z
30-
0
0 500 1000 1500
Carboplatin (RM)
Figure 6 Formation of carboplatin-DNA adducts in RIF-l and
CHO cells. Cells were treated for h with 0- 1.2 mm carboplatin,
washed, cultured for 24 h in carboplatin-free medium, and
immunostained for platinum-DNA binding. Each point
represents the mean ± s.e. from two slides; 30 nuclei per point.
in Figure 6. For CHO cells, a 4- to 5-fold higher concentra-
tion of carboplatin was required to reach the same level of
nuclear staining density as for RIF-I cells (Figure 6). This is
in contrast to the high ratio found for cells measured
immediately after exposure (Figure 2). The correlation
coefficients between the nuclear staining density (at 24 h) and
the surviving fractions were 0.95 for RIF-I cells and 0.99 for
CHO cells (P <0.01). When data from both cell lines were
combined, a good correlation remained (Figure 7; correlation
coefficient: 0.89; P <0.01). Comparison with data from the
cisDDP-treated groups showed that 41-48 times more moles
carboplatin than cisDDP were required to induce the same
level of nuclear staining density. Although a slightly different
regression line was obtained when data for cisDDP were
pooled with those for carboplatin, the coefficient of correla-
tion between nuclear staining density and surviving fraction
remained the same. This was true for each of the cell lines
and for the combined data of both lines (Figure 7). These
experiments showed that carboplatin-DNA adduct levels in
cultured cells correlated well with levels of cell killing. In
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Figure 7 Correlation between the sensitivity to carboplatin and
the carboplatin-DNA adduct-specific nuclear staining density.
Survival data from Figure 5 are plotted against the nuclear
staining densities from Figure 6. (RIF-1, *; CHO, 0). Also
shown are data for cisDDP-treated RIF-I (A) and CHO (A)
cells. The best fitting line, calculated by linear regression analysis,
concerns only the carboplatin data.
150
>_ ~ ~ Carboplatin
Ch ,)110
'E~~~~~~~~~~~~~~~2 co I
,50
Z cisDDP
o
0 5 10 15 20 25 30 35 40 45
Time after treatment (Hours)
Figure 8 Formation of carboplatin- and cisDDP-DNA adducts
in buccal cells from cancer patients vs the time after the end of
the infusions. Patients A (0) and B (A) received 600 and
800 mg m2 carboplatin, respectively, via a 2 h-infusion. Patient
C (*) received 75 mg m-2 cisDDP by a 230 min-infusion. Cells
were washed, fixed, and immunostained for platinum-DNA
adducts. Each point represents the mean ± s.e. from two slides;
30 nuclei per point.
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between 6 and 10 h (patient A) and between 6 and 14 h
(patient B). The observed maximum nuclear staining density
imol' carboplatin in buccal cells from patient B was 1.4
times higher than in those from patient A. Although the
number of time-points was relatively small for practical
reasons, the results suggest some interpatient variation. The
nuclear staining density in buccal cells from the cisDDP-
treated patient C showed no significant incease (P >0.05)
between 0 and 6 h after the end of the infusion (Figure 8),
showing that the level of cisDDP-DNA adducts was almost
maximal immediately after infusion. From the data shown in
Figure 8 it was calculated that a six times molar excess of
carboplatin over cisDDP was required to achieve the same
nuclear staining density in human buccal cells in situ.
Discussion
Carboplatin loses its cyclobutanedicarboxylato acid-ligand
when it bifunctionally binds to DNA. The ultimate inter-
action products of carboplatin with DNA are, therefore
probably chemically identical with those of cisDDP (Knox et
al., 1986; Dijt, 1989). This could explain why antiserum
NKI-A59 raised against cisDDP-modified DNA, also recog-
nises carboplatin-DNA adducts (Terheggen et al., 1988; com-
pare also Reed et al., 1987).
The binding ofcarboplatin to DNA in solution was shown
to proceed slower than that of cisDDP to DNA (Figure 1). It
is known that only aquated derivatives of cisDDP and carbo-
platin can bind to DNA (Zwelling & Kohn, 1979). Carbo-
platin's lower interaction rate with DNA can therefore be
explained by its aquation rate, which can be up to 100 times
lower than that of cisDDP (Cleare et al., 1978; Knox et al.,
1986). The relatively low aquation rate of carboplatin also
explains why relatively high concentrations of this drug are
required to obtain detectable adduct levels in cultured cells
(Figures 2 and 3). An additional explanation for the
relatively low adduct-specific immunostaining signals in the
latter experiments follows from Figure 4. This figure shows a
substantial increase in the adduct-specific immunosignal of
both CHO and RIF-1 cells after removal of carboplatin from
the incubation medium. Although it cannot be excluded that
these cells retain significant amounts ofunreacted carboplatin
after being washed twice, a more reasonable explanation
seems to be the post-treatment conversion of already formed
monofunctional carboplatin-DNA adducts into bidentate
adducts (Knox et al., 1986). Due to their bulky cyclo-
butanedicarboxylato acid group, the monovalent carboplatin-
DNA adducts might not be recognised by antiserum NKI-
A59, whereas the ultimate bidentate adducts, identical to
bidentate cisDDP-DNA adducts, will be recognised. The
relative contributions of these two factors, aquation rate and
adduct recognition, to the low initial staining after carbo-
platin is yet unknown.
Our findings in cultured cells are in agreement with those
reported in the literature. For example, carboplatin-DNA
adduct levels in cultured Walker and V79 cells were found to
be up to 40 times lower at a molar basis than cisDDP-DNA
adduct levels (Knox et al., 1986). The slow binding of car-
boplatin to DNA in solution (Figure 1) and, apparently, also
to DNA in cultured cells (Figure 4) is consistent with pub-
lished data on DNA-DNA cross-linking in cultured cells,
which is maximal at 18 h post-treatment for carboplatin and
between 6 and 12 h for cisDDP (Roberts & Friedlos, 1987).
These data are reminiscent of our present observation that
the in situ rate ofplatinum-DNA binding in buccal cells from
patients was markedly slower for carboplatin than for
cisDDP (Figure 8). Other in vivo data (on rat kidneys) also
suggest that carboplatin binds slower and to a much lower
extent to cellular DNA than does cisDDP (Terheggen, 1989).
However, it is emphasised that these in vivo data cannot be
compared directly with in vitro results (see below). In the
present study it was shown that the immunostaining signal
paralleled killing of cultured RIF-1 and CHO cells when
both parameters were measured at 24 h after treatment
(Figure 7). In fact, a 4-fold difference between the two cell
lines was found for both sensitivity to carboplatin and nuclear
staining density. A similar correlation has previously been
demonstrated for six cisDDP-treated mammalian cell lines
(Terheggen et al., 1990a). A comparison of Figure 2 with
Figure 6 shows that the difference in nuclear staining density
between RIF-1 and CHO cells was up to a factor 40 directly
after treatment with carboplatin, and only a factor 4 to 5 at
24 h. This discrepancy suggests that the rate of net DNA
adduction and/or the conversion rate of monovalent into
bidentate adducts in one (or both) of these cells is not
constant in time. Further investigations are needed to
confirm the observed difference and to discriminate between
the two possible explanations.
There was a marked difference between the in vitro and in
vivo data on DNA modification by carboplatin. When
highest levels of carboplatin-DNA binding were compared
with the highest levels of cisDDP-DNA adducts, 41-48 times
more moles carboplatin than cisDDP were required to reach
a given level of platinum-DNA binding in cultured RIF-1
and CHO cells (see Results). This factor was only 6 to 17
when buccal cells from carboplatin- and cisDDP-treated
cancer patients were compared (Figure 8; see Terheggen et
al., 1988) and 4.3 ± 1.3 (mean ± s.e.) for buccal cells from 11
patients treated with carboplatin and cisDDP on different
days (Terheggen et al., 1990b; study in cooperation with
F.M. Muggia, M.D., University of Southern California). An
explanation for this in vitro/in vivo difference could be as
follows. A lower binding level of carboplatin to DNA
relative to cisDDP may partially be due to a decreased drug
uptake. A prolonged drug exposure, as occurred in the
patients, would allow more time for the uptake of carbo-
platin. The prolonged availability of free carboplatin in the
blood plasma compared with that for free cisDDP (Calvert
et al., 1984) would therefore contribute to the difference
between in vivo and in vitro results.
A high correlation was shown between cell killing and the
level of platinum-DNA binding, when measured 24 h after
incubation with carboplatin (this paper) or directly after
exposure to cisDDP (Terheggen et al., 1990a). This suggests
that, irrespective of the cell type or the drug, the adduct-
specific immunostaining signal is a quantitative indicator for
in vitro cell kill, provided that time points of maximum DNA
adduction are studied. The latter condition might be impor-
tant especially for slowly reacting drugs like carboplatin. The
cell kill/adduct correlation and the ability of the antiserum to
detect carboplatin adducts at clinically relevant doses,
coupled with the knowledge of the optimal measuring time,
opens the possibility of immuno-staining tumour biopsy
material for drug sensitivity.
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